Kurin, Inc. Reports Record Revenue for 2022

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced record revenues for 2022. Revenue growth in 2022 was dramatic, increasing over 60% over 2021 revenue.

“We are pleased with Kurin’s success, as demonstrated by the impressive growth over 2021, which also saw a large revenue increase over the prior year,” said Bob Rogers, CEO of Kurin, Inc. “Our fourth quarter revenue reflected our highest sales quarter by some distance and we are very well positioned for continued strong growth in 2023.”

“In addition, we continue to roll out our proprietary Advance push-button needle, providing vertical integration that increases our shareholder value,” said Mr. Rogers. “We continue to build upon the company’s strong financial position and have accelerated our hiring to accommodate this growth.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Announces Successful FDA Audit

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced the results of their recent FDA inspection.

“I am pleased to announce Kurin has successfully passed an FDA inspection of our manufacturing procedures, records, and facilities,” said Bob Rogers, CEO and Inventor of Kurin. “In a recent unscheduled visit by the FDA, there were no observations of what are called a 483 non-conformance. We take pride in operating our company under Good Manufacturing Practices (GMP) and a robust Quality System. I am proud of our team for continuing to demonstrate our commitment to excellence and in consistently meeting federal requirements and our elevated expectations for quality.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, potentially exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening infections caused by C. diff.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Provides Update on Litigation Activity

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, provides an update to the most recent moves by Magnolia Medical Technologies. This week, Magnolia filed a motion in the US District Court of Delaware for a permanent injunction, hoping to take Kurin off the market.

“We are disappointed, but not surprised by their attempt to create a monopoly and deprive customers of the ability to choose the most appropriate solution for them,” said Bob Rogers, CEO and Inventor of Kurin. “We will vigorously defend access to the best solution to the contaminated blood culture problem. Our experience over the past few years shows that hospitals have rejected Magnolia’s Steripath product because it is unnecessarily complex and difficult to use.  Kurin’s innovation in developing a smaller, simpler device is a demonstration of how the intellectual property system should work in America and explains why we are the market leader. We will not be bullied by a venture-backed company who continues to spend their millions on litigation in hopes of creating a monopoly. We are heartened by the support of Kurin customers, and have been told they too are upset at Magnolia’s attempts to use the legal system to reduce choice and negatively impact clinical outcomes.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening infections caused by C. diff.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Announces Full Scale Manufacturing of Push-button Needle

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced that their previously mentioned Advance Safety Needle System has entered full scale production on their automated machine. The Advance needle was tested in 2021, has been used in Kurin accounts since last year and is now widely available.

“We are pleased with the transition to automated manufacturing of the Advance Safety Needle, as market demand for alternative needles has been strong,” said Bob Rogers, CEO of Kurin, Inc. “Needle manufacturers have created significant stress in the supply chain with widescale backorders and unprecedented price increases. With our Advance needle, we can better control product availability for the growing Kurin customer base, as well as entertain inquiries from strategic partners looking for their own push-button needle. In addition, we are pleased that Advance shows improved performance characteristics compared to traditional, retraction-oriented products.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening infections caused by C. diff.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Statement Regarding Patent Litigation

Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, today released a statement regarding results of a jury trial in the patent litigation brought by Magnolia Medical Technologies.

Magnolia Medical originally asserted four patents in the case. By the time of the trial, all of these patents were dropped, except one having only two asserted claims. The Delaware jury concluded that Kurin infringed the single Magnolia patent, and awarded a royalty on each Kurin Lock set sold during a certain time period. The verdict will not prevent Kurin from maintaining the uninterrupted supply of its market-leading Kurin Lock to hospitals – and will allow it to continue implementing its plans.

“While we strongly disagree with some aspects of the Jury’s decision, we are pleased that this chapter of the litigation has concluded and that it does not impede our ability to continue operating. The conclusion of this trial will allow us to return our focus to delivering Kurin Locks to the customers and patients who need them, and advancing this important solution to effectively address the blood culture contamination problem,” said Bob Rogers, Inventor and CEO of Kurin.

Kurin’s revolutionary and disruptive approach automatically and passively sidelines potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection. Contaminated blood cultures also create a financial burden to hospitals by prolonging hospital stays.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

U.S. District Court Enters Judgment of No Infringement of Patent Asserted Against Kurin Inc. by Magnolia Medical Technologies, Inc.

Kurin Inc., the inventor and manufacturer of Kurin® blood culture collection sets, announced that the U.S. District Court for the District of Delaware has entered a judgment that Kurin does not infringe U.S. Patent No. 9,855,001 in the patent-infringement lawsuit Magnolia brought against Kurin.  Magnolia earlier withdrew two other patents from the case, leaving just one of the four originally asserted patents for the upcoming trial.

“The fact that Magnolia has finally agreed to entry of a judgment of no infringement of this patent confirms yet again our longstanding belief that Magnolia’s case lacks merit,” said Bob Rogers, CEO of Kurin and inventor of the Kurin Lock. “As we said years ago when they filed this suit, we think Magnolia’s lawsuit reflects a belief that it cannot compete in the marketplace on the merits of its product. We look forward to defending ourselves against the last remaining patent in the upcoming trial.”

Rogers added “Kurin has quietly become the market leader by providing a simple, low cost and easy to use solution that customers prefer over other options, including Magnolia’s Steripath device.”

Kurin’s revolutionary approach to the contaminated blood culture problem is elegantly simple, an intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection in contrast to conventional diversion.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Announces Launch of Its Proprietary Push-button Needle System

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced that they have commenced the commercial launch of their push-button needle, to be used as part of Kurin blood culture sets. The Advance Safety Needle System was tested in 2021 and is now being sold into accounts using Kurin.

“We are proud to commercialize the Advance Safety Needle, as there has been market demand for alternatives and improvements in this space,” said Bob Rogers, CEO of Kurin, Inc. “We are pleased with our field trials performed over the past several months. In addition to the positive feedback that we received, our testing shows improved performance characteristics compared to traditional, retraction-oriented products. The development of the Advance Needle is an important milestone for Kurin, providing us a more reliable supply of product, better cost control, the opportunity to offer improved benefits over current needles, and creates new strategic opportunities in which we are already engaged.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Announces Agreement with AllSpire Health GPO to Impact Contaminated Blood Cultures

Kurin. Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture sets, announced the signing of a recent agreement with AllSpire Health GPO. The agreement is sole source and is for three years.

“AllSpire Health GPO and Kurin are committed to patient safety by providing innovative solutions designed to address a common source of contaminated blood cultures and in doing so, reducing overall healthcare costs,” said Bob Rogers, Inventor and CEO of Kurin. “We are pleased to be the only product on contract with AllSpire Health GPO to help their hospitals reduce contaminated blood cultures and are already engaged with their hospitals to help impact patient care and positively impact hospitals financially.”

“AllSpire Health GPO is excited to partner with Kurin and their blood culture products. This technology will be a great benefit to our members by reducing the financial impact of false positive results,” said James Wallick, Senior Director, Strategic Sourcing at AllSpire Health GPO.

About AllSpire Health GPO

AllSpire Health GPO, LLC is a group purchasing organization dedicated to reducing the total cost of healthcare through optimized purchase pricing, supply utilization management, regional collaborative service centers, and comprehensive clinical value analysis. www.allspiregpo.org

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Reports Record Sales for Q4 and Total 2021 Revenues

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced record revenues in December and the 4th quarter. 2021 revenue growth over 2020 was dramatic.

“Sepsis continues to be a critical challenge for hospitals, and helping them reduce their contaminated blood cultures is as important as ever,” said Bob Rogers, CEO of Kurin, Inc. “Kurin is simple to use and does not require a change in practice, helping hospitals address the critical issue of blood culture contamination.”

“The pandemic continues to present challenges to everyone and I give credit to our team for their persistence and diligence in helping hospitals when they need it most,” said Mr. Rogers. “We continue to build upon the company’s strong financial position.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Reports Record Q3 Sales

Kurin, Inc., the inventor and manufacturer of Kurin® blood culture collection sets, announced that 3rd quarter revenues continued their record growth with the largest quarterly revenue in the company’s history. Kurin also reports that Q3 revenue grew 121% over revenue in the third quarter of 2019, before the pandemic began and a 43% increase over revenue in the third quarter of 2020, during the pandemic.

“Our continued growth during these challenging times is a testament to the quality of our professional team and the simplicity of Kurin,” said Bob Rogers, CEO of Kurin, Inc. “Hospitals are navigating through unprecedented times, but still must provide optimal care. Because Kurin does not require a change in practice, we are helping hospitals address the critical issue of blood culture contamination in a seamless manner.”

“Although any company would be pleased with this growth, it is particularly satisfying to note that each successive month of the quarter established new revenue highs, demonstrating continued acceleration of our business,” said Mr. Rogers. “We have been cash flow positive for months and this growth enables us to invest in increased capacity and some exciting future projects.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.